Clavis Pharma ASA said a Phase 3 trial of its lipid-conjugated therapy for patients with acute myeloid leukaemia (AML) failed to meet its endpoint of a significant survival advantage and that all development work with the compound will be stopped. ---Subscribe to MedNous to access this article--- Company News
